

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Bezlotoxumab Formulation

Version  
3.0

Revision Date:  
2025/04/14

SDS Number:  
809011-00021

Date of last issue: 2024/09/28  
Date of first issue: 2016/07/22

### 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Bezlotoxumab Formulation

#### Manufacturer or supplier's details

Company : MSD

Address : 199 Wenhai North Road  
HEDA, Hangzhou - Zhejiang Province - CHINA 310018

Telephone : +1-908-740-4000

Emergency telephone number : 86-571-87268110

E-mail address : EHSDATASTEWARD@msd.com

#### Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

### 2. HAZARDS IDENTIFICATION

#### Emergency Overview

**Appearance** : Aqueous solution  
**Colour** : Colorless to pale yellow  
**Odour** : No data available

Not a hazardous substance or mixture.

#### GHS Classification

||| Not a hazardous substance or mixture.

#### GHS label elements

||| No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

#### Physical and chemical hazards

Not classified based on available information.

#### Health hazards

Not classified based on available information.

#### Environmental hazards

Not classified based on available information.

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Bezlotoxumab Formulation

Version  
3.0

Revision Date:  
2025/04/14

SDS Number:  
809011-00021

Date of last issue: 2024/09/28  
Date of first issue: 2016/07/22

### Other hazards which do not result in classification

None known.

## 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

### Components

Chemical name	CAS-No.	Concentration (% w/w)
Bezlotoxumab	1246264-45-8	>= 1 -< 10

## 4. FIRST AID MEASURES

If inhaled : If inhaled, remove to fresh air.  
Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap as a precaution.  
Get medical attention if symptoms occur.

In case of eye contact : Flush eyes with water as a precaution.  
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention if symptoms occur.  
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : None known.

Protection of first-aiders : No special precautions are necessary for first aid responders.

Notes to physician : Treat symptomatically and supportively.

## 5. FIREFIGHTING MEASURES

Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Bezlotoxumab Formulation

Version 3.0	Revision Date: 2025/04/14	SDS Number: 809011-00021	Date of last issue: 2024/09/28 Date of first issue: 2016/07/22
----------------	------------------------------	-----------------------------	---

Special protective equipment for firefighters : Wear self-contained breathing apparatus for firefighting if necessary.  
Use personal protective equipment.

## 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Prevent spreading over a wide area (e.g. by containment or oil barriers).  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.  
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.  
Clean up remaining materials from spill with suitable absorbent.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

## 7. HANDLING AND STORAGE

### Handling

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Take care to prevent spills, waste and minimize release to the environment.

Avoidance of contact : Oxidizing agents

### Storage

Conditions for safe storage : Keep in properly labelled containers.  
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Bezlotoxumab Formulation

Version  
3.0

Revision Date:  
2025/04/14

SDS Number:  
809011-00021

Date of last issue: 2024/09/28  
Date of first issue: 2016/07/22

Strong oxidizing agents

Packaging material : Unsuitable material: None known.

## 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

### Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Bezlotoxumab	1246264-45-8	TWA	5.0 mg/m <sup>3</sup> (OEB 1)	Internal

**Engineering measures** : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections). All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Laboratory operations do not require special containment.

### Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type  
Eye/face protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.

Hand protection  
Material : Chemical-resistant gloves

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

## 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : Aqueous solution

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Bezlotoxumab Formulation

Version 3.0      Revision Date: 2025/04/14      SDS Number: 809011-00021      Date of last issue: 2024/09/28  
Date of first issue: 2016/07/22

---

Colour : Colorless to pale yellow  
Odour : No data available  
Odour Threshold : No data available  
pH : 5.7 - 6.3  
Melting point/freezing point : No data available  
Initial boiling point and boiling range : No data available  
Flash point : No data available  
Evaporation rate : No data available  
Flammability (solid, gas) : Not applicable  
Flammability (liquids) : No data available  
Upper explosion limit / Upper flammability limit : No data available  
Lower explosion limit / Lower flammability limit : No data available  
Vapour pressure : No data available  
Relative vapour density : No data available  
Relative density : No data available  
Density : 1.0146 g/cm<sup>3</sup>  
Solubility(ies)  
Water solubility : No data available  
Partition coefficient: n-octanol/water : Not applicable  
Auto-ignition temperature : No data available  
Decomposition temperature : No data available  
Viscosity  
Viscosity, dynamic : 1.2 mPa.s ( 25 °C)  
Viscosity, kinematic : 1.833 mm<sup>2</sup>/s ( 4 °C)  
1.183 mm<sup>2</sup>/s ( 25 °C)

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Bezlotoxumab Formulation

Version 3.0      Revision Date: 2025/04/14      SDS Number: 809011-00021      Date of last issue: 2024/09/28  
Date of first issue: 2016/07/22

---

Explosive properties	: Not explosive
Oxidizing properties	: The substance or mixture is not classified as oxidizing.
Molecular weight	: No data available
Particle characteristics	
Particle size	: Not applicable

---

## 10. STABILITY AND REACTIVITY

Reactivity	: Not classified as a reactivity hazard.
Chemical stability	: Stable under normal conditions.
Possibility of hazardous reactions	: Can react with strong oxidizing agents.
Conditions to avoid	: None known.
Incompatible materials	: Oxidizing agents
Hazardous decomposition products	: No hazardous decomposition products are known.

---

## 11. TOXICOLOGICAL INFORMATION

Exposure routes	: Inhalation Skin contact Ingestion Eye contact
-----------------	--

### Acute toxicity

Not classified based on available information.

### Components:

#### **Bezlotoxumab:**

Acute toxicity (other routes of administration)	: LD50 (Mouse): > 125 mg/kg Application Route: Intravenous Remarks: No adverse effect has been observed in acute toxicity tests.
---	--

### **Skin corrosion/irritation**

Not classified based on available information.

### **Serious eye damage/eye irritation**

Not classified based on available information.

### **Respiratory or skin sensitisation**

### **Skin sensitisation**

Not classified based on available information.

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Bezlotoxumab Formulation

Version  
3.0

Revision Date:  
2025/04/14

SDS Number:  
809011-00021

Date of last issue: 2024/09/28  
Date of first issue: 2016/07/22

---

### Respiratory sensitisation

Not classified based on available information.

### Germ cell mutagenicity

Not classified based on available information.

### Carcinogenicity

Not classified based on available information.

### Reproductive toxicity

Not classified based on available information.

### STOT - single exposure

Not classified based on available information.

### STOT - repeated exposure

Not classified based on available information.

### Repeated dose toxicity

#### Components:

##### Bezlotoxumab:

Species	:	Mouse
NOAEL	:	50 mg/kg
Application Route	:	Intravenous
Exposure time	:	15 d
Remarks	:	No significant adverse effects were reported

Species	:	Mouse
NOAEL	:	125 mg/kg
Application Route	:	Intravenous
Exposure time	:	21 d
Remarks	:	No significant adverse effects were reported

### Aspiration toxicity

Not classified based on available information.

### Experience with human exposure

#### Components:

##### Bezlotoxumab:

Inhalation	:	Symptoms: Nausea, Headache, Diarrhoea, Fever
------------	---	--

## 12. ECOLOGICAL INFORMATION

### Ecotoxicity

No data available

### Persistence and degradability

No data available

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Bezlotoxumab Formulation

Version  
3.0

Revision Date:  
2025/04/14

SDS Number:  
809011-00021

Date of last issue: 2024/09/28  
Date of first issue: 2016/07/22

---

### Bioaccumulative potential

No data available

### Mobility in soil

No data available

### Other adverse effects

No data available

---

## 13. DISPOSAL CONSIDERATIONS

### Disposal methods

Waste from residues	: Do not dispose of waste into sewer. Dispose of in accordance with local regulations.
Contaminated packaging	: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

---

## 14. TRANSPORT INFORMATION

### International Regulations

#### UNRTDG

UN number	: Not applicable
Proper shipping name	: Not applicable
Class	: Not applicable
Subsidiary risk	: Not applicable
Packing group	: Not applicable
Labels	: Not applicable
Environmentally hazardous	: no

#### IATA-DGR

UN/ID No.	: Not applicable
Proper shipping name	: Not applicable
Class	: Not applicable
Subsidiary risk	: Not applicable
Packing group	: Not applicable
Labels	: Not applicable
Packing instruction (cargo aircraft)	: Not applicable
Packing instruction (passenger aircraft)	: Not applicable

#### IMDG-Code

UN number	: Not applicable
Proper shipping name	: Not applicable
Class	: Not applicable
Subsidiary risk	: Not applicable
Packing group	: Not applicable
Labels	: Not applicable
EmS Code	: Not applicable
Marine pollutant	: no

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Bezlotoxumab Formulation

Version  
3.0

Revision Date:  
2025/04/14

SDS Number:  
809011-00021

Date of last issue: 2024/09/28  
Date of first issue: 2016/07/22

---

### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

### National Regulations

#### GB 6944/12268

UN number	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
Marine pollutant	:	no

#### Special precautions for user

Not applicable

---

## 15. REGULATORY INFORMATION

### National regulatory information

#### Law on the Prevention and Control of Occupational Diseases

#### Regulations on Safety Management of Hazardous Chemicals

Catalogue of Hazardous Chemicals	:	This product is not listed in the catalogue of hazardous chemicals and it does not meet the definition of hazardous chemicals and its principles of determination.
----------------------------------	---	--

Identification of Major Hazard Installations for Hazardous Chemicals (GB 18218)	:	Not listed
---	---	------------

Hazardous Chemicals for Priority Management under SAWS	:	Not listed
--	---	------------

Catalogue of Specially Controlled Hazardous Chemicals	:	Not listed
---	---	------------

List of Explosive Precursors	:	Not listed
------------------------------	---	------------

#### Regulations on Labour Protection in Workplaces where Toxic Substances are Used

Catalogue of Highly Toxic Chemicals	:	Not listed
-------------------------------------	---	------------

#### Regulation of Environmental Management on the First Import of Chemicals and the Import and Export of Toxic Chemicals

China Severely Restricted Toxic Chemicals for Import and Export	:	Not listed
---	---	------------

#### Regulation on the Administration of Precursor Chemicals

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Bezlotoxumab Formulation

Version 3.0	Revision Date: 2025/04/14	SDS Number: 809011-00021	Date of last issue: 2024/09/28
			Date of first issue: 2016/07/22

Catalogue and Classification of Precursor Chemicals : Not listed

### Yangtze River Protection Law

This product does not contain any dangerous chemicals prohibited for inland river transport.

### Regulations of Ozone Depleting Substances Management

List of Controlled Ozone Depleting Substances Import and Export : Not listed  
List of Controlled Ozone Depleting Substances : Not listed

### Environmental Protection Law

List of Priority Controlled Chemicals : Not listed  
List of Key Controlled New Pollutants : Not listed

### The components of this product are reported in the following inventories:

AICS : not determined  
DSL : not determined  
IECSC : not determined

## 16. OTHER INFORMATION

Revision Date : 2025/04/14

### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : yyyy/mm/dd

### Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory con-

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Bezlotoxumab Formulation

Version 3.0	Revision Date: 2025/04/14	SDS Number: 809011-00021	Date of last issue: 2024/09/28 Date of first issue: 2016/07/22
----------------	------------------------------	-----------------------------	---

centration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

### Disclaimer

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CN / EN